Home » Stocks » EPIX

ESSA Pharma Inc. (EPIX)

Stock Price: $26.84 USD -0.38 (-1.40%)
Updated Jun 21, 2021 12:01 PM EDT - Market open
Market Cap 1.10B
Revenue (ttm) n/a
Net Income (ttm) -28.96M
Shares Out 40.46M
EPS (ttm) -0.98
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 21
Last Price $26.84
Previous Close $27.22
Change ($) -0.38
Change (%) -1.40%
Day's Open 27.12
Day's Range 26.67 - 27.47
Day's Volume 16,895
52-Week Range 5.20 - 36.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

HOUSTON, Texas and VANCOUVER, Canada, May 25, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies...

3 weeks ago - PRNewsWire

- Presented promising preliminary pharmacokinetic and clinical data on EPI-7386 in metastatic castration-resistant prostate cancer at 2021 AACR - Raised approximately $150 million in a public offering H...

1 month ago - PRNewsWire

HOUSTON, Texas and VANCOUVER, Canada, April 28, 2021 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapi...

1 month ago - PRNewsWire

HOUSTON, Texas and VANCOUVER, Canada, April 14, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapi...

2 months ago - PRNewsWire

HOUSTON, Texas and VANCOUVER, Canada, April 10, 2021 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therap...

2 months ago - PRNewsWire

HOUSTON, Texas and VANCOUVER, BC, March 26, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies f...

2 months ago - PRNewsWire

VANCOUVER, BC and HOUSTON, March 4, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the ...

3 months ago - PRNewsWire

HOUSTON and VANCOUVER, BC, Feb. 25, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX) (TSX-V: EPI), a clinical stage pharmaceutical company focused on developing novel therap...

3 months ago - PRNewsWire

HOUSTON, Texas and VANCOUVER, Canada, Feb. 25, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapi...

3 months ago - PRNewsWire

VANCOUVER, BC and HOUSTON, Feb. 22, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the ...

3 months ago - PRNewsWire

VANCOUVER, BC and HOUSTON, Feb. 17, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the ...

4 months ago - PRNewsWire

VANCOUVER, BC and HOUSTON, Feb. 16, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the ...

4 months ago - PRNewsWire

ESSA Pharma Inc. (NASDAQ: EPIX) shares are trading higher after the company reported first-quarter earnings results and highlighted the presentation of Phase 1 pharmacology data of EPI-7386 for advanced...

Other stocks mentioned: ANAB, PACB
4 months ago - Benzinga

VANCOUVER, BC and HOUSTON, Feb. 11, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the ...

4 months ago - PRNewsWire

VANCOUVER, BC and HOUSTON, Feb. 11, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the ...

4 months ago - PRNewsWire

VANCOUVER and HOUSTON, Dec. 15, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the trea...

6 months ago - PRNewsWire

HOUSTON and VANCOUVER, BC, Nov. 10, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the t...

7 months ago - PRNewsWire

HOUSTON and VANCOUVER, BC, Oct. 26, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI) (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing novel therap...

7 months ago - PRNewsWire

HOUSTON and VANCOUVER, BC, Oct. 24, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of pr...

7 months ago - PRNewsWire

HOUSTON and VANCOUVER, BC, Sept. 21, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSX-V: EPI; ) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel the...

9 months ago - PRNewsWire

HOUSTON and VANCOUVER, BC, Sept. 17, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of ...

9 months ago - PRNewsWire

HOUSTON and VANCOUVER, BC, Sept. 14, 2020 /PRNewswire/ - ESSA Pharma Inc.

9 months ago - PRNewsWire

ESSA's EPI-7386 novel approach to treat prostate cancer by targeting the N-terminal domain androgen receptor inhibitor is now in Phase 1 trials. The first patient was dosed on July 15.

10 months ago - Seeking Alpha

VANCOUVER, BC and HOUSTON, Aug. 6, 2020 /PRNewswire/ - ESSA Pharma Inc.

10 months ago - PRNewsWire

HOUSTON and VANCOUVER, BC, July 31, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel thera...

10 months ago - PRNewsWire

VANCOUVER, BC and HOUSTON, July 28, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel thera...

10 months ago - PRNewsWire

HOUSTON and VANCOUVER, BC, July 15, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of pr...

11 months ago - PRNewsWire

HOUSTON and VANCOUVER, BC, June 22, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX); (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of p...

11 months ago - PRNewsWire

ESSA recently presented promising new data on its next-generation EPI-7386 N-terminal domain androgen receptor inhibitor at ESMO for the treatment of prostate cancer.

1 year ago - Seeking Alpha

ESSA Pharma (EPIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 years ago - Zacks Investment Research

About EPIX

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Founded
2009
Stock Exchange
NASDAQ
Ticker Symbol
EPIX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for ESSA Pharma stock is "Strong Buy." The 12-month stock price forecast is 0.75, which is a decrease of -97.21% from the latest price.

Price Target
$0.75
(-97.21% downside)
Analyst Consensus: Strong Buy